Advancing therapeutic options in multiple sclerosis with neuroprotective properties

Area of Science:

• Neuroimmunology
• Neurodegeneration
• Multiple Sclerosis Pathophysiology

Background:

• Central nervous system (CNS) inflammation is a hallmark of multiple sclerosis (MS).
• Neurodegeneration in MS occurs independently of inflammation, affecting both lesions and normal-appearing white matter.
• Neurotrophic factors mediate neuroprotection, with immune cells potentially enhancing these pathways.

Purpose of the Study:

• To explore neuroprotective autoimmunity in multiple sclerosis.
• To evaluate measurement strategies for neurodegeneration and neuroprotection.
• To assess the neuroprotective capacity of MS therapeutics.

Main Methods:

• Utilizing clinical parameters, magnetic resonance imaging (MRI), diffusion tensor imaging (DTI), and optical coherence tomography (OCT).
• Investigating the role of neurotrophic factors and immune cells in neuroprotection.
• Examining established therapies like glatiramer acetate, laquinimod, and dimethyl fumarate.

Main Results:

• Neuroprotective autoimmunity offers a potential therapeutic avenue.
• Multimodal measurements are crucial for assessing neuroprotective effects.
• Established MS drugs demonstrate capacity to enhance endogenous neuroprotection.

Conclusions:

• Elucidating neuroprotective pathways is vital for understanding MS complexity.
• Enhancing endogenous neuroprotection is a promising therapeutic strategy for MS.
• Improved therapeutic approaches targeting neuroprotection can mitigate long-term disability and cognitive decline in MS.